EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Evaluation of safety and early efficacy of AAV gene therapy in mouse models of vanishing white matter disease

Jessica A Herstine, Pi-Kai Chang, Sergiy Chornyy, Tamara J Stevenson, Alex C Sunshine, Ksenia Nokhrina, Jessica Rediger, Julia Wentz, Tatyana A Vetter, Erika Scholl, Caleb Holaway, Nettie K Pyne und 5 weitere

Molecular Therapy · 2024

DOI: 10.1016/j.ymthe.2024.03.034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2024. Verfasst von Jessica A Herstine und 16 weiteren Autor:innen. Beteiligte Einrichtung: Center for Gene Therapy, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH 43215, USA; Department of Pediatrics, The Oh…. Hauptthemen laut MEDLINE: Dependovirus, Disease Models, Animal, Leukoencephalopathies, Genetic Therapy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCRR NIH HHS, NCATS NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Leukoencephalopathy with vanishing white matter (VWM) is a progressive incurable white matter disease that most commonly occurs in childhood and presents with ataxia, spasticity, neurological degeneration, seizures, and premature death. A distinctive feature is episodes of rapid neurological deterioration provoked by stressors such as infection, seizures, or trauma. VWM is caused by autosomal recessive mutations in one of five genes that encode the eukaryotic initiation factor 2B complex, which is necessary for protein translation and regulation of the integrated stress response. The majority of mutations are in EIF2B5. Astrocytic dysfunction is central to pathophysiology, thereby constituting a potential therapeutic target. Herein we characterize two VWM murine models and investigate astrocyte-targeted adeno-associated virus serotype 9 (AAV9)-mediated EIF2B5 gene supplementation therapy as a therapeutic option for VWM. Our results demonstrate significant rescue in body weight, motor function, gait normalization, life extension, and finally, evidence that gene supplementation attenuates demyelination. Last, the greatest rescue results from a vector using a modified glial fibrillary acidic protein (GFAP) promoter-AAV9-gfaABC(1)D-EIF2B5-thereby supporting that astrocytic targeting is critical for disease correction. In conclusion, we demonstrate safety and early efficacy through treatment with a translatable astrocyte-targeted gene supplementation therapy for a disease that has no cure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DependovirusDisease Models, AnimalLeukoencephalopathiesGenetic TherapyGenetic VectorsAstrocytesEukaryotic Initiation Factor-2BAnimalsMiceGlial Fibrillary Acidic ProteinHumans

Stichwörter der Autor:innen

AAV9EIF2B5MRIVWMastrocytesgene supplementationgene therapyintegrated stress responseleukodystrophymyelinvanishing white matter disease

Substanzen

Eukaryotic Initiation Factor-2BGlial Fibrillary Acidic Protein

Autor:innen und Institutionen

  • Center for Gene Therapy, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH 43215, USA; Department of Pediatrics, The Ohio State University, Columbus, OH 43210, USA; Center for Clinical and…
  • Department of Pediatrics, The University of Utah School of Medicine, Salt Lake City, UT 84113, USA.
  • Center for Gene Therapy, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH 43215, USA.
  • Center for Gene Therapy, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH 43215, USA; Department of Neurology, Nationwide Children's Hospital, Columbus, OH 43205, USA.
  • Center for Gene Therapy, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH 43215, USA; Department of Pediatrics, The Ohio State University, Columbus, OH 43210, USA.
  • Small Animal Imaging Core, The Ohio State University, Columbus, OH 43210, USA.

Förderung

  • NCRR NIH HHS
  • NCATS NIH HHS
  • NINDS NIH HHS
  • National Center for Advancing Translational Sciences
  • National Center for Research Resources
  • American Board of Psychiatry and Neurology Inc
  • Abigail Wexner Research Institute at Nationwide Children's Hospital
  • The Ohio State University Center for Clinical and Translational Science

Zitieren

APA

Herstine, J. A., Chang, P. K., Chornyy, S., Stevenson, T. J., Sunshine, A. C., Nokhrina, K., Rediger, J., Wentz, J., Vetter, T. A., Scholl, E., Holaway, C., Pyne, N. K., Bratasz, A., Yeoh, S., Flanigan, K. M., Bonkowsky, J. L., & Bradbury, A. M. (2024). Evaluation of safety and early efficacy of AAV gene therapy in mouse models of vanishing white matter disease. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2024.03.034

Vancouver

Herstine JA, Chang PK, Chornyy S, Stevenson TJ, Sunshine AC, Nokhrina K, et al. Evaluation of safety and early efficacy of AAV gene therapy in mouse models of vanishing white matter disease. Molecular Therapy. 2024. doi:10.1016/j.ymthe.2024.03.034

BibTeX
@article{Herstine2024,
  author = {Herstine, Jessica A and Chang, Pi-Kai and Chornyy, Sergiy and Stevenson, Tamara J and Sunshine, Alex C and Nokhrina, Ksenia and Rediger, Jessica and Wentz, Julia and Vetter, Tatyana A and Scholl, Erika and Holaway, Caleb and Pyne, Nettie K and Bratasz, Anna and Yeoh, Stewart and Flanigan, Kevin M and Bonkowsky, Joshua L and Bradbury, Allison M},
  title = {Evaluation of safety and early efficacy of AAV gene therapy in mouse models of vanishing white matter disease},
  journal = {Molecular Therapy},
  year = {2024},
  doi = {10.1016/j.ymthe.2024.03.034}
}
Kostenlos starten →